Visken 15mg tablets

País: Regne Unit

Idioma: anglès

Font: MHRA (Medicines & Healthcare Products Regulatory Agency)

ingredients actius:

Pindolol

Disponible des:

Advanz Pharma

Codi ATC:

C07AA03

Designació comuna internacional (DCI):

Pindolol

Dosis:

15mg

formulario farmacéutico:

Oral tablet

Vía de administración:

Oral

clase:

No Controlled Drug Status

tipo de receta:

Valid as a prescribable product

Resumen del producto:

BNF: 02040000; GTIN: 5060064170465

Fitxa tècnica

1.
NAME OF THE MEDICINAL PRODUCT
Visken 15 mg_ _Tablets
Pindolol 15mg Tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 15 mg pindolol.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet.
White, round, flat, bevelled tablets, marked ‘Visken 15’ on one
side and with a score line on the
other.
The score line is only to facilitate breaking for ease of swallowing
and not to divide into equal
doses.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
_ _
This medicine is indicated in adults for the treatment of essential
hypertension. It is also used as a
prophylactic treatment of angina pectoris.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
POSOLOGY
_ _
Adults
_Essential Hypertension: _Initially one 5 mg tablet two or three times
a day. According to the
response of the patient the dose may be increased at weekly intervals
to a maximum of 45 mg
given in divided doses twice or three times daily.
_ _
_Once daily dosage schedule: _Further work shows that many patients
respond to a once daily
dosage regime. Initially 15 mg (3 tablets) should be taken once a day
with breakfast and adjusted
according to individual response up to a maximum of 45 mg (9 tablets).
Most patients respond to
a once daily dose of between 15-30 mg (3-6 tablets).
The onset of action of this medicine is usually rapid, with most
patients showing a response
within the first one to two weeks of treatment. However, the maximum
response may take several
weeks to develop.
_ _
_Prophylactic treatment of Angina pectoris: _Usually 2.5 mg to 5 mg
orally three times a day
according to response. It reduces the frequency and severity of
anginal attacks and increases work
capacity.
Paediatric population
The safety and efficacy of this medicine in children has not been
established. Its use is therefore
not recommended.
Use in the elderly
No evidence exists that elderly patients require different dosages or
show different side-effects
from younger patients.
Route of administration
Oral.
4.3
CONTRAINDICATIONS
This m